NovoCure Ltd NVCR

Rank #2264 · Nasdaq · $1.5B market cap

Audited by KOST FORER GABBAY & KASIERERA Member of EY Global, no going-concern flag in the latest filing.

Score

26.8

P/E

-7.4

P/B

3.45

ROE

-46.9%

Op. Margin

-45.7%

Debt Ratio

200%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -7.4x, P/B 3.45x. Ranks in the top 71% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -46.9%. Ranks in the top 87% of the universe.

Safety ★★☆☆☆

Weak

Debt ratio 200%. Ranks in the top 62% of the universe.

Growth ★☆☆☆☆

Weak

Revenue decline of 5.3% year over year. Ranks in the top 76% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	–	$-0.1B	$-0.1B	$0.0B	–	40
2016	–	$-0.1B	$-0.1B	$0.2B	–	33
2017	–	$-0.1B	$-0.1B	$0.1B	–	143
2018	$0.1B	$-0.1B	$-0.1B	$0.3B	-139.1	60
2019	$0.2B	$-0.0B	$-0.1B	$0.1B	-22.2	160
2020	$0.2B	$-0.0B	$-0.1B	$0.1B	-13.6	230
2021	$0.4B	$-0.0B	$-0.0B	$0.1B	-0.3	513
2022	$0.5B	$0.0B	$0.0B	$0.2B	6.1	335
2023	$0.5B	$-0.0B	$-0.1B	$0.5B	-8.3	157
2024	$0.5B	$-0.1B	$-0.1B	$0.4B	-16.6	191
2025	$0.5B	$-0.2B	$-0.2B	$0.4B	-45.7	200